{
    "doi": "https://doi.org/10.1182/blood.V116.21.4613.4613",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=1681",
    "start_url_page_num": 1681,
    "is_scraped": "1",
    "article_title": "Incidence of Cytogenetic Abnormalities In Newly Diagnosed Binet Stage A CLL and Relationship with Prognostic Biomarkers and with Stereotyped B Cell Receptors: Updated Results on 344 Patients Included In the Prospective O-CLL1 GISL Study. ",
    "article_date": "November 19, 2010",
    "session_type": "CLL - BIOLOGY AND PATHOPHYSIOLOGY, EXCLUDING THERAPY",
    "topics": [
        "chromosome abnormality",
        "prognostic marker",
        "receptors, antigen, b-cell",
        "biological markers",
        "brachial plexus neuritis",
        "karyotype determination procedure",
        "disease progression",
        "zap-70 kinase",
        "cancer",
        "immunoglobulins"
    ],
    "author_names": [
        "Sonia Fabris, PhD",
        "Giovanna Cutrona, PhD",
        "Massimo Gentile",
        "Serena Matis, PhD",
        "Emanuela Anna Pesce",
        "Francesco Maura",
        "Gabriella Ciceri",
        "Francesco Di Raimondo",
        "Caterina Musolino",
        "Marco Gobbi",
        "Nicola Di Renzo, MD",
        "Francesca Romana Mauro",
        "Renato Cantaffa",
        "Maura Brugiatelli, MD",
        "Francesco Merli, MD",
        "Simonetta Zupo",
        "Caterina Mammi",
        "Luca Baldini",
        "Francesco Angrilli, MD",
        "Gianni Quintana",
        "Ugo Consoli, MD",
        "Giovanni Bertoldero",
        "Emilio Iannitto, MD",
        "Paolo Di Tonno",
        "Antonio Fragasso",
        "Stefano Molica, MD",
        "Pellegrino Musto",
        "Maria Cristina Cox",
        "Gainluca Festini",
        "Vincenzo Callea",
        "Stefano Sacchi",
        "Agostino Cortelezzi, MD",
        "Giorgio Lambertenghi Deliliers",
        "Robin Foa\u0300",
        "Massimo Federico, MD",
        "Fortunato Morabito",
        "Manlio Ferrarini, Prof",
        "Antonino Neri, Prof"
    ],
    "author_affiliations": [
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "U.O.C. di Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy, "
        ],
        [
            "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "GISL Trial Office, Modena, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Dipartimento di Scienze Biomediche, Divisione di Ematologia, Universita\u0300 di Catania & Ospedale Ferrarotto, Catania, Italy, "
        ],
        [
            "Divisione di Ematologia, Universita\u0300 di Messina, Messina, Italy, "
        ],
        [
            "Dipartimento di Ematologia e Oncologia, Universita\u0300 di Genova, Genova, Italy, "
        ],
        [
            "Unita\u0300 di Ematologia, Ospedale Vito Fazzi, Lecce, Italy, "
        ],
        [
            "Divisione di Ematologia, Universita\u0300 La Sapienza, Roma, Italy, "
        ],
        [
            "Ematologia, Azienda Ospedaliera di Catanzaro, Catanzaro, Italy, "
        ],
        [
            "Divisione di Ematologia, Azienda Ospedaliera Papardo, Messina, Italy, "
        ],
        [
            "Unita\u0300 Operativa di Ematologia, A.O.S. Maria Nuova, Reggio Emilia, Italy, "
        ],
        [
            "SS Malattie Linfoproliferative, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "Unita\u0300 Operativa di Ematologia, A.O.S. Maria Nuova, Reggio Emilia, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Dipartimento di Ematologia, Ospedale Santo Spirito, Pescara, Italy, "
        ],
        [
            "Divisione di Ematologia, Presidio Ospedaliero A.Perrino, Brindisi, Italy, "
        ],
        [
            "UOS di Emato-Oncologia, Ospedale Garibaldi Nesima, Catania, Italy, "
        ],
        [
            "Dipartimento di Oncologia, Ospedale Civile, Noale, Venezia, Italy, "
        ],
        [
            "Divisione di Ematologia, Ospedale Policlinico, Palermo, Italy, "
        ],
        [
            "Dipartimento di Ematologia,Venere, Ospedale Bari Carbonara, Bari, "
        ],
        [
            "Unita\u0300 Operativa di Medicina Interna, Presidio Ospedaliero di Matera, Matera, Italy, "
        ],
        [
            "Dip di Oncologia ed Ematologia, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy, "
        ],
        [
            "Dipartimento di Onco-Ematologia e Unita\u0300 di Oncologia Molecolare, IRCCS, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture (Pz), Italy, "
        ],
        [
            "Ematologia, A.O. Sant\u2019Andrea, Universita\u2019 La Sapienza, Roma, Italy, "
        ],
        [
            "Centro di Riferimento Ematologico-Seconda Medicina, Azienda Ospedaliero-Universitaria, Ospedali Riuniti, Trieste, Italy, "
        ],
        [
            "Divisione di Ematologia, Azienda Ospedaliera, Reggio Calabria, Italy, "
        ],
        [
            "Dip Oncologia ed Ematologia, Universita\u0300 Modena Centro Oncologico Modenese, Policlinico, Modena, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ],
        [
            "Divisione di Ematologia, Universita\u0300 La Sapienza, Roma, Italy, "
        ],
        [
            "Cattedra di Oncologia Medica, Universita\u0300 di Modena e Reggio Emilia, Modena, Italy"
        ],
        [
            "U.O.C. di Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy, "
        ],
        [
            "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche, Ematologia 1 CTMO, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Universita\u0300 di Milano, Milano, Italy, "
        ]
    ],
    "first_author_latitude": "45.459492600000004",
    "first_author_longitude": "9.19477725",
    "abstract_text": "Abstract 4613 Background: Biologic risk factors such as immunoglobulin variable heavy chain (IgV H ) gene mutation status and CD38 and ZAP-70 expression levels, along with genomic aberrations, have been integrated in clinical prognostic evaluation of CLL. Additionaly, CLL subsets expressing a certain stereotyped B-cell receptors have also been indicated to share biological and clinical features. Aims: We investigated, by FISH, the incidence of the major cytogenetic alterations (+12 and 13q14, 17p13, 11q23 deletions), their clinical implication and their relationship with prognostic biomarkers in 344 out of 384 Binet A CLLs enrolled in the prospective multicenter O-CLL1 GISL trial. Stereotypy subsets identification have been performed in 324 patients. Methods: Molecular markers characterization and FISH protocols were previously reported (Cutrona et al. Haematologica , 2008; Fabris et al. Genes Chromosomes Cancer , 2008), while stereotyped subsets were defined according to Stamatopoulos et al ( Blood , 2007) and Murray et al ( Blood , 2008). Results: At least one abnormality was found in 225/344 (65.4%) cases. The most frequent abnormality was del(13q14), detected in 173 CLLs (50.3%) followed by +12 (44/344;12.8%) (one case harboring 17p13 deletion), del(17p13) (9/344, 2.6%) and del(11q23) (18/344, 5.2%). 13q14 deletion was found as a sole abnormality in 155 (45%) patients; in the remaining cases, it was combined with +12 (3 pts) and 17p13 (4 pts) or 11q23 deletions (11 pts). The 13q deletion was found as a monoallelic deletion in 139/173 (80.3%); the presence of a biallelic deletion (> 20% of interphase nuclei) was found in the remaining 34 cases. No acquisition of new cytogenetic aberrations was evidenced among the 13 CLLs developing progressive disease (range, 6 to 32 months; median, 20 months); in only one case, the proportion of nuclei with 17p13 and 13q14 deletions increased from the time of diagnosis (from 33% to 92%). Biomarkers data were available in all of the patients. CD38 percentages (mean value \u00b1 sem) were 7.9\u00b11.3, 15.1\u00b11.9, 51.7\u00b15.5, 22.0\u00b17.8,40.8\u00b113.2, 39.8\u00b17.3 for del(13q14), normal karyotype, +12, del(11q23), del(17p13) and multiple alterations, respectively (p<0.0001). The percentages of IgVH mutations significantly correlated with cytogenetic alterations; namely, 5.7\u00b10.2 for cases with del(13q14), 4.7\u00b10.4 for normal karyotype, 2.3\u00b10.5 for +12, 0.05\u00b10.05 for del(11q23), 2.0\u00b11.1 for del(17p13) and 1.0\u00b10.4 for multiple alterations (p<0.0001). Similarly, a significant correlation was found for ZAP-70 expression: namely 32.9\u00b11.6 for cases with del(13q14), 38.5\u00b12.1 for normal karyotype, 46.4\u00b13.6 for +12, 67.0\u00b18.3 for del(11q22), 41.0\u00b112.8 for del(17p13) and 50.7\u00b15.4 multiple alterations (p<0.0001). Cytogenetic abnormalities were clustered in 3 risk groups [i.e. low del(13q14) and normal; intermediate (+12); and high risk 17p13 and 11q23 deletions] and correlated with a scoring system in which patients were stratified in 4 different groups according to the absence or presence of 1, 2 or 3 biomarkers (Morabito et al., Br. J. Haematol., 2009). Notably, 166/175 cases scoring 0, gathered in the low FISH group, whereas 21/26 high FISH risk cases clustered in scoring 2\u20133 (p<0.0001). A significantly higher risk of starting treatment was found in high vs. intermediate (p=0.024) and low FISH risk (p=0.001) CLLs. Finally, stereotyped IgVH sequences were found in 108/324 (33%). Unfavorable stereotyped subsets (#1, #2, #3, #7 and #9) were significantly more frequent in CLLs with poor-prognostic aberrations (p=0.0203; RR=3.589). Conclusions: Our data indicate that cytogenetic lesions predicting unfavorable prognosis show a relatively low incidence in newly diagnosed Binet stage A CLLs and are significantly associated with negative prognostic biomarkers predictive of disease progression. Our prospective study also confirms the prognostic value of risk FISH categories in predicting the time to the first treatment and revealed a higher rate of unfavorable stereotyped IgV H subsets in patients carrying poor-prognostic genomic aberrations. Finally, preliminary evidence in a limited number of cases indicates that the acquisition of new genetic abnormalities seem to be an infrequent event during disease progression. Disclosures: No relevant conflicts of interest to declare."
}